Lysophospholipid signal molecules act as determinants of conflicting actions of the lipoproteins.

本研究旨在探讨脂蛋白中溶血磷脂的抗动脉粥样硬化作用。在内皮细胞中，HDL的抗动脉粥样硬化作用通过两条信号通路介导，即鞘氨醇1-磷酸(S1P)/S1P受体和载脂蛋白A/清道夫受体B类I型受体（SR-BI）。LDL抑制Apo A/SR-BI信号转导系统，但对S1P/S1P受体无抑制作用。HDL所含S1P的抗动脉粥样硬化作用不受LDL的抑制。

The aim of this study was to investigate the antiatherogenic actions of lysophospholipid contained in lipoproteins. In the endothelial cells, the antiatherogenic actions of HDL was mediated through two signaling pathways, both sphingosine 1-phosphate(S1P)/S1P receptors and Apo A/scavenger receptor class B type I receptors(SR-BI). LDL inhibited the signal transduction system of Apo A/SR-BI, but not S1P/S1P receptors. The antiatherogenic action of S1P contained in HDL was not inhibited by LDL.